Ajanta Pharmaceuticals Ltd. — documents
162 files on disk. SHA-256 from the acquisition manifests; links open the exchange copy.
| Class | Period | Scope / kind | Filing date | File | SHA-256 |
|---|---|---|---|---|---|
| Results XBRL (NSE) | 2018-03-31 | Standalone | — | INDAS_34782_8032_03052018024305_WEB.xml | 4033068621980171 |
| Results XBRL (NSE) | 2018-03-31 | Consolidated | — | INDAS_34782_8032_03052018024305_WEB_2.xm | 2b0c43b2059942ad |
| Results XBRL (NSE) | 2018-09-30 | Standalone | — | INDAS_39942_56927_01112018045414_WEB.xml | e4b0a6a5498aaab5 |
| Results XBRL (NSE) | 2018-09-30 | Consolidated | — | INDAS_39942_56927_01112018045414_WEB_2.x | f4ce67420dd5ae20 |
| Results XBRL (NSE) | 2018-12-31 | Standalone | — | INDAS_43487_83972_22022019031335_WEB.xml | b85ef2c1760e993b |
| Results XBRL (NSE) | 2018-12-31 | Consolidated | — | INDAS_43487_83972_22022019031335_WEB_2.x | b256b908bf2d2334 |
| Results XBRL (NSE) | 2019-03-31 | Consolidated | — | INDAS_43735_100286_02052019033423_WEB.xm | c9ccc8b9a8c3f37c |
| Results XBRL (NSE) | 2019-03-31 | Standalone | — | INDAS_43736_100288_02052019033806_WEB.xm | 011682d154fd149a |
| Results XBRL (NSE) | 2019-06-30 | Standalone | — | INDAS_46510_127005_01082019103238_WEB.xm | 49f733bcd622fcc6 |
| Results XBRL (NSE) | 2019-06-30 | Consolidated | — | INDAS_46511_127008_01082019103509_WEB.xm | 0f829b72b298f5ba |
| Results XBRL (NSE) | 2019-09-30 | Consolidated | — | INDAS_49299_160334_06112019112152_WEB.xm | abfd1c3f2f2cd9d8 |
| Results XBRL (NSE) | 2019-09-30 | Standalone | — | INDAS_49301_160341_06112019112336_WEB.xm | 95c424902856f40d |
| Results XBRL (NSE) | 2019-12-31 | Consolidated | — | INDAS_52553_215323_06022020105908_WEB.xm | 19276022545b6382 |
| Results XBRL (NSE) | 2019-12-31 | Standalone | — | INDAS_52554_215326_06022020110017_WEB.xm | dde8765f905eaed0 |
| Results XBRL (NSE) | 2020-03-31 | Standalone | — | INDAS_55244_260064_21052020120333_WEB.xm | 91944d74779d9fb4 |
| Results XBRL (NSE) | 2020-03-31 | Consolidated | — | INDAS_55245_260068_21052020120544_WEB.xm | ed860301b4dbf6b3 |
| Results XBRL (NSE) | 2020-06-30 | Standalone | — | INDAS_58749_300082_31072020103644_WEB.xm | 34c1a9673901fa3c |
| Results XBRL (NSE) | 2020-06-30 | Consolidated | — | INDAS_58751_300088_31072020103817_WEB.xm | 74d9134162de2392 |
| Results XBRL (NSE) | 2020-09-30 | Standalone | — | INDAS_63026_354416_04112020032417_WEB.xm | 848f5cb1b592f5d2 |
| Results XBRL (NSE) | 2020-09-30 | Consolidated | — | INDAS_63027_354420_04112020032538_WEB.xm | 2a24c3cb9df531c1 |
| Results XBRL (NSE) | 2020-12-31 | Consolidated | — | INDAS_66855_401305_03022021100416_WEB.xm | aad7568777417240 |
| Results XBRL (NSE) | 2020-12-31 | Standalone | — | INDAS_66856_401308_03022021100530_WEB.xm | 838e39257af8bb10 |
| Results XBRL (NSE) | 2021-03-31 | Consolidated | — | INDAS_69606_445414_01052021023807_WEB.xm | c5b4bea4840a7ba9 |
| Results XBRL (NSE) | 2021-03-31 | Standalone | — | INDAS_69607_445417_01052021024000_WEB.xm | 3e5b5ebadd282f78 |
| Results XBRL (NSE) | 2021-06-30 | Standalone | — | INDAS_73700_497708_30072021121917_WEB.xm | b058afe8cef145f3 |
| Results XBRL (NSE) | 2021-06-30 | Consolidated | — | INDAS_73702_497714_30072021122031_WEB.xm | 79847a613832f730 |
| Results XBRL (NSE) | 2021-09-30 | Standalone | — | INDAS_77479_549914_01112021093820_WEB.xm | 7bd2d33d3042e2dd |
| Results XBRL (NSE) | 2021-09-30 | Consolidated | — | INDAS_77486_549961_01112021113442_WEB.xm | e1bb64e901334dc8 |
| Results XBRL (NSE) | 2021-12-31 | Standalone | — | INDAS_80844_601279_31012022054101_WEB.xm | 512f0c531e953d6a |
| Results XBRL (NSE) | 2021-12-31 | Consolidated | — | INDAS_80845_601282_31012022054235_WEB.xm | 3b12eb9bc60b2174 |
| Results XBRL (NSE) | 2022-03-31 | Standalone | — | INDAS_84211_652827_11052022105530_WEB.xm | 2c8be0bd14bd34e2 |
| Results XBRL (NSE) | 2022-03-31 | Consolidated | — | INDAS_84212_652830_11052022105723_WEB.xm | 76e8d8dcd5df430b |
| Results XBRL (NSE) | 2022-06-30 | Consolidated | — | INDAS_612189_2809_29072022102050_WEB.xml | 75bcdbd39f8f54b5 |
| Results XBRL (NSE) | 2022-09-30 | Standalone | — | INDAS_838025_5150_04112022165850_WEB.xml | c29575b4834ac368 |
| Results XBRL (NSE) | 2022-09-30 | Consolidated | — | INDAS_838026_5150_04112022165850_WEB.xml | 9ad613c42dabf64a |
| Results XBRL (NSE) | 2022-12-31 | Standalone | — | INDAS_88323_783458_02022023111250_WEB.xm | 66c842ba436b52c2 |
| Results XBRL (NSE) | 2022-12-31 | Consolidated | — | INDAS_88324_783463_02022023111421_WEB.xm | 02e07ad91dca3b92 |
| Results XBRL (NSE) | 2023-03-31 | Consolidated | — | INDAS_91250_837984_05052023055426.xml | ffd6190278023ca6 |
| Results XBRL (NSE) | 2023-03-31 | Standalone | — | INDAS_91251_837987_05052023055622.xml | 90f4fe698157e0ab |
| Results XBRL (NSE) | 2023-06-30 | Standalone | — | INDAS_94723_901926_27072023071356.xml | 5eee16150b814c8a |
| Results XBRL (NSE) | 2023-06-30 | Consolidated | — | INDAS_94725_901939_27072023071558.xml | a3a33add0c5776c0 |
| Results XBRL (NSE) | 2023-09-30 | Standalone | — | INDAS_98318_972344_31102023052756.xml | 6f7b686862b81b8b |
| Results XBRL (NSE) | 2023-09-30 | Consolidated | — | INDAS_98320_972364_31102023053643.xml | fefe3be657360e5f |
| Results XBRL (NSE) | 2023-12-31 | Standalone | — | INDAS_101935_1040889_31012024081329.xml | 33868655509e7283 |
| Results XBRL (NSE) | 2023-12-31 | Consolidated | — | INDAS_101936_1040896_31012024081644.xml | e81e9d1adeefeee5 |
| Results XBRL (NSE) | 2024-03-31 | Standalone | — | INDAS_105172_1114070_02052024074347.xml | 6425ae6257175e54 |
| Results XBRL (NSE) | 2024-03-31 | Consolidated | — | INDAS_105173_1114087_02052024075035.xml | 3a20229c2832f051 |
| Results XBRL (NSE) | 2024-06-30 | Standalone | — | INDAS_109792_1206475_30072024041326.xml | 9e79263e51f0c9d6 |
| Results XBRL (NSE) | 2024-06-30 | Consolidated | — | INDAS_109832_1206826_30072024060010.xml | 27dc91ec5cc3a8ea |
| Results XBRL (NSE) | 2024-09-30 | Standalone | — | INDAS_113747_1291825_29102024111731.xml | fd54bfcf896968fd |
| Results XBRL (NSE) | 2024-09-30 | Consolidated | — | INDAS_113749_1291841_29102024112224.xml | 0f003fc973cafd80 |
| Results XBRL (NSE) | 2024-12-31 | Consolidated | — | INDAS_118161_1366089_30012025051110.xml | 86a252a18350aa67 |
| Results XBRL (NSE) | 2024-12-31 | Standalone | — | INDAS_118165_1366143_30012025052543.xml | 679b142b10e31461 |
| Results XBRL (NSE) | 2025-03-31 | Consolidated | — | INTEGRATED_FILING_INDAS_1429258_30042025 | 47b67026925e9759 |
| Results XBRL (NSE) | 2025-03-31 | Standalone | — | INTEGRATED_FILING_INDAS_1429340_30042025 | 1a1f5fea5f862a84 |
| Results XBRL (NSE) | 2025-06-30 | Standalone | — | INTEGRATED_FILING_INDAS_1495181_28072025 | a58c598fbb8cd3fd |
| Results XBRL (NSE) | 2025-06-30 | Consolidated | — | INTEGRATED_FILING_INDAS_1495199_28072025 | 7c05cf45a65256e6 |
| Results XBRL (NSE) | 2025-09-30 | Consolidated | — | INTEGRATED_FILING_INDAS_1563647_03112025 | 5668f45f7f24d0ca |
| Results XBRL (NSE) | 2025-09-30 | Standalone | — | INTEGRATED_FILING_INDAS_1563791_03112025 | 14ab56df996662de |
| Results XBRL (NSE) | 2025-12-31 | Standalone | — | INTEGRATED_FILING_INDAS_1614462_30012026 | 58040ab62c95f561 |
| Results XBRL (NSE) | 2025-12-31 | Consolidated | — | INTEGRATED_FILING_INDAS_1614540_30012026 | 281eb7cc29ef1583 |
| Results XBRL (NSE) | 2026-03-31 | Consolidated | — | INTEGRATED_FILING_INDAS_1663654_05052026 | fd85f2fb0b881621 |
| Results XBRL (NSE) | 2026-03-31 | Standalone | — | INTEGRATED_FILING_INDAS_1663679_05052026 | 826b642c4c0b9fd5 |
| Results XBRL (NSE) | 2026-06-30 | Standalone | — | INTEGRATED_FILING_INDAS_1705073_30072026 | 1306aa465979efdb |
| Results XBRL (NSE) | 2026-06-30 | Consolidated | — | INTEGRATED_FILING_INDAS_1705089_30072026 | dc364e771c0f2834 |
| Results XBRL (BSE) | 2018-06-30 | Standalone | 2018-07-31T17:06:41 | Main_Ind_As_532331_317201817626.xml | d0467d916c7206ab |
| Results XBRL (BSE) | 2018-06-30 | Consolidated | 2018-07-31T17:06:41 | Main_Ind_As_532331_317201817716.xml | 2dccffe235a81627 |
| Results XBRL (BSE) | 2018-09-30 | Standalone | 2018-11-01T10:25:02 | Main_Ind_As_532331_1112018102444.xml | c3babdeb183432d9 |
| Results XBRL (BSE) | 2018-09-30 | Consolidated | 2018-11-01T10:25:02 | Main_Ind_As_532331_1112018102556.xml | 9a065b0ef0456858 |
| Results XBRL (BSE) | 2018-12-31 | Standalone | 2019-01-31T12:10:33 | Main_Ind_As_532331_3112019121015.xml | 13aee06bcde8c62c |
| Results XBRL (BSE) | 2018-12-31 | Consolidated | 2019-01-31T12:10:33 | Main_Ind_As_532331_311201912917.xml | 624fd771798d6a5a |
| Results XBRL (BSE) | 2019-03-31 | Consolidated | 2019-05-02T11:39:47 | Main_Ind_As_532331_252019113545.xml | 3f385b65ec7d0f1d |
| Results XBRL (BSE) | 2019-03-31 | Standalone | 2019-05-02T11:39:47 | Main_Ind_As_532331_252019113844.xml | faeddb9014c9b0c7 |
| Results XBRL (BSE) | 2019-06-30 | Standalone | 2019-08-01T10:22:40 | Main_Ind_As_532331_182019102230.xml | 37186b9d7b74b9e9 |
| Results XBRL (BSE) | 2019-06-30 | Consolidated | 2019-08-01T10:22:40 | Main_Ind_As_532331_182019102259.xml | 9fb74ba8373b7eeb |
| Results XBRL (BSE) | 2019-09-30 | Consolidated | 2019-11-06T12:13:05 | Main_Ind_As_532331_611201911431.xml | 03ac3815b7845b22 |
| Results XBRL (BSE) | 2019-09-30 | Standalone | 2019-11-06T12:13:05 | Main_Ind_As_532331_611201911529.xml | 3f94c933c7f29e48 |
| Results XBRL (BSE) | 2019-12-31 | Consolidated | 2020-02-06T11:38:40 | Main_Ind_As_532331_622020105141.xml | ceaae9dd75a87500 |
| Results XBRL (BSE) | 2019-12-31 | Standalone | 2020-02-06T11:38:40 | Main_Ind_As_532331_622020105224.xml | a66320820363be25 |
| Results XBRL (BSE) | 2020-03-31 | Standalone | 2020-05-21T13:32:55 | Main_Ind_As_532331_2152020113331.xml | bd8daf6466f85772 |
| Results XBRL (BSE) | 2020-03-31 | Consolidated | 2020-05-21T13:32:55 | Main_Ind_As_532331_2152020113435.xml | ea9b69a293ed15cb |
| Results XBRL (BSE) | 2020-06-30 | Standalone | 2020-07-31T12:14:54 | Main_Ind_As_532331_3172020103344.xml | 21a843617d9cfa60 |
| Results XBRL (BSE) | 2020-06-30 | Consolidated | 2020-07-31T12:14:54 | Main_Ind_As_532331_317202010336.xml | 9103acafbbb6cd2a |
| Results XBRL (BSE) | 2020-09-30 | Consolidated | 2020-11-04T15:05:42 | Main_Ind_As_532331_411202015419.xml | bd10872353794fe2 |
| Results XBRL (BSE) | 2020-09-30 | Standalone | 2020-11-04T15:05:42 | Main_Ind_As_532331_41120201556.xml | 628c2b5cef732740 |
| Results XBRL (BSE) | 2020-12-31 | Consolidated | 2021-02-03T11:36:16 | Main_Ind_As_532331_3220211003.xml | 38f21ffb84b3fcc5 |
| Results XBRL (BSE) | 2020-12-31 | Standalone | 2021-02-03T11:36:16 | Main_Ind_As_532331_3220211018.xml | 26fa4721a4c17d71 |
| Results XBRL (BSE) | 2021-03-31 | Consolidated | 2021-05-03T13:27:26 | Main_Ind_As_532331_152021143054.xml | c5813ac48f488236 |
| Results XBRL (BSE) | 2021-03-31 | Standalone | 2021-05-03T13:27:26 | Main_Ind_As_532331_152021143221.xml | 0b9a4ef59794cdf6 |
| Results XBRL (BSE) | 2021-06-30 | Standalone | 2021-07-30T12:18:32 | Main_Ind_As_532331_3072021115411.xml | 21b16dfd415cc300 |
| Results XBRL (BSE) | 2021-06-30 | Consolidated | 2021-07-30T12:18:32 | Main_Ind_As_532331_3072021115520.xml | 49515681d023fa07 |
| Results XBRL (BSE) | 2021-09-30 | Consolidated | 2021-11-01T11:48:45 | Main_Ind_As_532331_1112021112842.xml | 673c66c0afa74064 |
| Results XBRL (BSE) | 2021-09-30 | Standalone | 2021-11-01T11:48:45 | Main_Ind_As_532331_111202193220.xml | 1963660602322c52 |
| Results XBRL (BSE) | 2021-12-31 | Standalone | 2022-01-31T18:18:07 | Main_Ind_As_532331_3112022173627.xml | 27e56f3cdab51dc5 |
| Results XBRL (BSE) | 2021-12-31 | Consolidated | 2022-01-31T18:18:07 | Main_Ind_As_532331_3112022173712.xml | b77957787955e242 |
| Results XBRL (BSE) | 2022-03-31 | Standalone | 2022-05-11T12:36:01 | Main_Ind_As_532331_1152022102719.xml | 6c557da1e407fc58 |
| Results XBRL (BSE) | 2022-03-31 | Consolidated | 2022-05-11T12:36:01 | Main_Ind_As_532331_1152022102940.xml | 28888071257fb8f5 |
| Results XBRL (BSE) | 2022-06-30 | Consolidated | 2022-07-29T12:47:20 | Main_Ind_As_532331_2972022101451.xml | 75bcdbd39f8f54b5 |
| Results XBRL (BSE) | 2022-06-30 | Standalone | 2022-07-29T12:47:20 | Main_Ind_As_532331_2972022101549.xml | f656c40c77304511 |
| Results XBRL (BSE) | 2022-09-30 | Consolidated | 2022-11-04T15:08:48 | Main_Ind_As_532331_4112022103958.xml | 9ad613c42dabf64a |
| Results XBRL (BSE) | 2022-09-30 | Standalone | 2022-11-04T15:08:48 | Main_Ind_As_532331_4112022104111.xml | c29575b4834ac368 |
| Annual report | 2016-03-31 | grade A | 2016-07-05T00:00:00 | 5323310316.pdf | d911b218a5858142 |
| Annual report | 2017-03-31 | grade A | 2017-07-05T00:00:00 | 5323310317.pdf | 18b1a3e59ec11154 |
| Annual report | 2018-03-31 | grade A | 2018-07-05T00:00:00 | 5323310318.pdf | af27dcb3522170c1 |
| Annual report | 2019-03-31 | grade A | 2019-06-20T00:00:00 | 5323310319.pdf | 0a2787f77666a4a2 |
| Annual report | 2020-03-31 | grade A | 2020-06-30T00:00:00 | 5323310320.pdf | 6c52f52cf49e4cde |
| Annual report | 2021-03-31 | grade A | 2021-06-15T00:00:00 | 68571532331.pdf | 7995c79868cfd99c |
| Annual report | 2022-03-31 | grade A | 2022-07-06T00:00:00 | 73503532331.pdf | c59832d0a19ec43b |
| Annual report | 2023-03-31 | grade A | 2023-06-16T12:36:46.013 | b20f31a7-e77a-42e1-9eeb-ccdb0a7b3320.pdf | 4ad3644e069ebb41 |
| Annual report | 2024-03-31 | grade A | 2024-06-18T14:15:03.283 | 34cfa17e-5471-4104-8264-eddcbd1dfd1e.pdf | 67ff4f032b0a5186 |
| Annual report | 2025-03-31 | grade A | 2025-06-18T14:11:06.737 | d052b71a-1a88-4eb9-9613-be4da52ec369.pdf | 52e875afc304cadb |
| Annual report | 2026-03-31 | grade A | 2026-06-18T10:49:36.74 | 9aa8b4aa-2d68-4133-aca5-456656e479a3.pdf | 3c0df643c841e1c6 |
| Concall | 2021-03-31 | COVER_LETTER | — | Date_20210504_Ajanta Pharmaceuticals Ltd._Concal_Q4FY21.pdf | f8e9c8dd1d5a3229 |
| Concall | 2021-06-30 | COVER_LETTER | — | Date_20210722_Ajanta Pharmaceuticals Ltd._Concal_Q1FY22.pdf | 173d9096b0ae4101 |
| Concall | 2021-06-30 | COVER_LETTER | — | Date_20210802_Ajanta Pharmaceuticals Ltd._Concal_Q1FY22.pdf | 825e4b7b92a608f4 |
| Concall | 2021-09-30 | COVER_LETTER | — | Date_20211108_Ajanta Pharmaceuticals Ltd._Concal_Q2FY22.pdf | 5f45980c56e64ec8 |
| Concall | 2021-12-31 | COVER_LETTER | — | Date_20220204_Ajanta Pharmaceuticals Ltd._Concal_Q3FY22.pdf | d65fd0f02b157a68 |
| Concall | 2022-03-31 | COVER_LETTER | — | Date_20220514_Ajanta Pharmaceuticals Ltd._Concal_Q4FY22.pdf | b2fac325d53c22fa |
| Concall | 2022-06-30 | TRANSCRIPT | — | Date_20220803_Ajanta Pharmaceuticals Ltd._Concal_Q1FY23.pdf | 2fb3510648c55f67 |
| Concall | 2022-09-30 | COVER_LETTER | — | Date_20221110_Ajanta Pharmaceuticals Ltd._Concal_Q2FY23.pdf | dc11b02524fb87ab |
| Concall | 2022-12-31 | COVER_LETTER | — | Date_20230213_Ajanta Pharmaceuticals Ltd._Concal_Q3FY23.pdf | 9bde8acb0f03ed87 |
| Concall | 2023-03-31 | COVER_LETTER | — | Date_20230511_Ajanta Pharmaceuticals Ltd._Concal_Q4FY23.pdf | 19de8a044312508c |
| Concall | 2023-06-30 | COVER_LETTER | — | Date_20230802_Ajanta Pharmaceuticals Ltd._Concal_Q1FY24.pdf | d90866c0f201c971 |
| Concall | 2023-09-30 | COVER_LETTER | — | Date_20231103_Ajanta Pharmaceuticals Ltd._Concal_Q2FY24.pdf | 049b6941a2fd52fc |
| Concall | 2023-12-31 | COVER_LETTER | — | Date_20240205_Ajanta Pharmaceuticals Ltd._Concal_Q3FY24.pdf | 087f1fd866dc6c1d |
| Concall | 2024-03-31 | COVER_LETTER | — | Date_20240508_Ajanta Pharmaceuticals Ltd._Concal_Q4FY24.pdf | 5e3690eb448b0f29 |
| Concall | 2024-06-30 | COVER_LETTER | — | Date_20240802_Ajanta Pharmaceuticals Ltd._Concal_Q1FY25.pdf | 3e97dbc974845d54 |
| Concall | 2024-09-30 | COVER_LETTER | — | Date_20241030_Ajanta Pharmaceuticals Ltd._Concal_Q2FY25.pdf | 884f4cdfad083f59 |
| Concall | 2024-12-31 | COVER_LETTER | — | Date_20250203_Ajanta Pharmaceuticals Ltd._Concal_Q3FY25.pdf | ca5a4fda498f8496 |
| Concall | 2025-03-31 | COVER_LETTER | — | Date_20250505_Ajanta Pharmaceuticals Ltd._Concal_Q4FY25.pdf | 2e1731b5f4714c92 |
| Concall | 2025-06-30 | COVER_LETTER | — | Date_20250731_Ajanta Pharmaceuticals Ltd._Concal_Q1FY26.pdf | 52dccfca21a9d6aa |
| Concall | 2025-09-30 | COVER_LETTER | — | Date_20251106_Ajanta Pharmaceuticals Ltd._Concal_Q2FY26.pdf | c47c2d9af9bf9686 |
| Concall | 2025-12-31 | COVER_LETTER | — | Date_20260205_Ajanta Pharmaceuticals Ltd._Concal_Q3FY26.pdf | 6fdb8974ce23d6c1 |
| Concall | 2026-03-31 | COVER_LETTER | — | Date_20260508_Ajanta Pharmaceuticals Ltd._Concal_Q4FY26.pdf | 0fc6cd25238111c7 |
| Concall | 2026-06-30 | COVER_LETTER | — | Date_20260803_Ajanta Pharmaceuticals Ltd._Concal_Q1FY27.pdf | d2ff843b3e667657 |
| Shareholding XBRL | 2021-09-30 | — | — | SHP_161879_532865_14102021024824_WEB.xml | 8bd713f2184ff5e3 |
| Shareholding XBRL | 2021-12-31 | — | — | SHP_164167_583796_12012022104615_WEB.xml | c446b51a1b47b9a5 |
| Shareholding XBRL | 2022-03-31 | — | — | SHP_166571_631086_12042022120544_WEB.xml | 3c2bf84275140694 |
| Shareholding XBRL | 2022-06-30 | — | — | SHP_169367_688522_14072022124307_WEB.xml | 8b0f6c65612f195d |
| Shareholding XBRL | 2022-09-30 | — | — | SHP_171011_720757_10102022043448_WEB.xml | 33cde340f8b420ba |
| Shareholding XBRL | 2022-12-31 | — | — | SHP_174329_767579_16012023030450_WEB.xml | 370444bfb30e4fbe |
| Shareholding XBRL | 2023-03-31 | — | — | SHP_176271_815605_12042023022235_WEB.xml | 8d94473af634aa5a |
| Shareholding XBRL | 2023-04-19 | — | — | SHP_178064_833012_26042023104447_WEB.xml | b62f5d1c3111e3ab |
| Shareholding XBRL | 2023-06-30 | — | — | SHP_178316_876115_07072023041937_WEB.xml | f4ef47bb2e0d9488 |
| Shareholding XBRL | 2023-09-30 | — | — | SHP_180901_944965_10102023021257_WEB.xml | 76a1889cd3d50582 |
| Shareholding XBRL | 2023-12-31 | — | — | SHP_183938_1017797_12012024122802_WEB.xm | 7dbdca961015bd43 |
| Shareholding XBRL | 2024-03-31 | — | — | SHP_186511_1089834_12042024050414_WEB.xm | 378d77d6f32f98c4 |
| Shareholding XBRL | 2024-06-30 | — | — | SHP_189192_1181594_12072024122138_WEB.xm | 8d03e515754e5722 |
| Shareholding XBRL | 2024-09-30 | — | — | SHP_191533_1264746_10102024035931_WEB.xm | 089c10766eccb0d5 |
| Shareholding XBRL | 2024-12-31 | — | — | SHP_193931_1338707_07012025042812_WEB.xm | 9d6d89d80adb6325 |
| Shareholding XBRL | 2025-03-31 | — | — | SHP_196632_1410929_09042025041226_WEB.xm | 6b8c02bb40629a00 |
| Shareholding XBRL | 2025-06-30 | — | — | SHP_1485343_17072025033256_WEB.xml | 28fabf92f7413f46 |
| Shareholding XBRL | 2025-09-30 | — | — | SHP_1547486_14102025034050_WEB.xml | c773c617b29bc569 |
| Shareholding XBRL | 2025-12-31 | — | — | SHP_1598406_12012026114131_WEB.xml | 504ce40a1e6594c0 |
| Shareholding XBRL | 2026-03-31 | — | — | SHP_1649511_13042026112752_WEB.xml | 3a7bc4fc36e614aa |
| Shareholding XBRL | 2026-06-30 | — | — | SHP_1692098_14072026024314_WEB.xml | 924a0e170a71369f |
| Related-party XBRL | 2022-03-31 | — | — | RPT_AJANTPHARM_25072022142026.xml | 3e272db03ca3112f |
| Related-party XBRL | 2022-09-30 | — | — | RPT_AJANTPHARM_14112022163351.xml | 52f6d262c919593b |
| Related-party XBRL | 2023-03-31 | — | — | RPT_837936_05052023051626_WEB.xml | a57c3cc0dde4a9ef |
| Related-party XBRL | 2023-09-30 | — | — | RPT_972318_31102023051714_WEB.xml | 1d585d16b36b4c35 |
| Related-party XBRL | 2024-03-31 | — | — | RPT_1114031_02052024072244_WEB.xml | 0e821ecf94477e55 |
| Related-party XBRL | 2024-09-30 | — | — | RPT_1291167_28102024061725_WEB.xml | 797116ba72dcad57 |